Basic information Safety Supplier Related

2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate

Basic information Safety Supplier Related

2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate Basic information

Product Name:
2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate
Synonyms:
  • GSK2983559 free acid
  • 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate
  • Ethanol, 2-[[4-(5-benzothiazolylamino)-6-[(1,1-dimethylethyl)sulfonyl]-7-quinazolinyl]oxy]-, 1-(dihydrogen phosphate)
  • Ethanol,2-[[4-(5-benzothiazolylamino)-6-[(1,1-dimethylethyl)sulfonyl]-7-quinazolinyl]oxy]-,dihydrogenphosphate(ester)
  • GSK2983559 (compound 3)
  • inhibit,THP-1 cell,RIP kinase,GSK 2983559,GSK2983559 free acid,Inhibitor,GSK-2983559,RIPK,Receptor-interacting protein kinases,GSK-2983559 free acid,GSK2983559
  • GSK2983559 (compound 3) ，S8927
CAS:
1579965-12-0
MF:
C21H23N4O7PS2
MW:
538.53
EINECS:
604-604-1
Mol File:
1579965-12-0.mol
More
Less

2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate Chemical Properties

Boiling point:
823.6±75.0 °C(Predicted)
Density 
1.537±0.06 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
DMF: slightly soluble; DMSO: 1 mg/ml; PBS (pH 7.2): 1 mg/ml
form 
A crystalline solid
pka
1.76±0.10(Predicted)
color 
Light yellow to yellow
More
Less

2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate Usage And Synthesis

Uses

GSK2983559 free acid (compound 3) is an orally active and potent receptor interacting protein 2 (RIP2) kinase inhibitor. GSK2983559 free acid can block many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples[1].

in vivo

GSK2983559 (oral gavage; 3 and 10 mg/kg; once) inhibits effectively MDP-induced IL-6 in mouse[2].

Animal Model:C57BL/6 mice (female) injected with MDP (100 μg)[2]
Dosage:3 and 10 mg/kg
Administration:Oral gavage; 3 and 10 mg/kg; once
Result:Suppressed serum IL-6 levels in a dose-dependent manner.

IC 50

RIPK2

References

[1] Haile PA, et al. Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. J Med Chem. 2019 Jul 25;62(14):6482-6494. DOI:10.1021/acs.jmedchem.9b00575
[2] Shuwei Wu, et al. Design, synthesis, and structure-activity relationship of novel RIPK2 inhibitors. Bioorg Med Chem Lett. 2022 Sep 2;75:128968. DOI:10.1016/j.bmcl.2022.128968

2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphateSupplier

Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696，15000506266 15000506266
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Email
3008007409@qq.com
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com
Shanghai SuperLan Chemcial Technique Centre
Tel
0-2022843681 15618226720
Email
chaolaichem@foxmail.com
Chuzhou KeMail Chemical Technology Co., Ltd
Tel
0550-5196001 15000891977
Email
wj520wjxby@126.com
More
Less

2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate(1579965-12-0)Related Product Information